Brief: Xbrane, STADA welcome EMA Positive Opinion For Ranibizumab Biosimilar Candidate Ximluci

Xbrane Biopharma AB

16/09/2022 12:44

Sept 16 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * STADA AND XBRANE WELCOME EMA POSITIVE OPINION FOR
RANIBIZUMAB
BIOSIMILAR CANDIDATE XIMLUCI
    * EUROPEAN MEDICINES AGENCY'S (EMA'S) COMMITTEE FOR
MEDICINAL
PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION FOR
XIMLUCI®, A BIOSIMILAR CANDIDATE REFERENCING LUCENTIS®
(RANIBIZUMAB)

Source text for Eikon:  ID:nMFN6C2DGT 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))